683 Capital Management LLC purchased a new stake in ContraFect Corp (NASDAQ:CFRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,600,000 shares of the biotechnology company’s stock, valued at approximately $2,886,000. 683 Capital Management LLC owned about 3.53% of ContraFect as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of CFRX. White Pine Capital LLC increased its holdings in shares of ContraFect by 0.3% in the second quarter. White Pine Capital LLC now owns 253,870 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 825 shares during the last quarter. Birchview Capital LP increased its holdings in shares of ContraFect by 56.5% in the third quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after purchasing an additional 410,000 shares during the last quarter. Finally, Fosun International Ltd acquired a new stake in shares of ContraFect in the third quarter valued at approximately $9,435,000. 62.47% of the stock is owned by hedge funds and other institutional investors.
ContraFect Corp (NASDAQ:CFRX) traded down $0.01 during trading hours on Friday, hitting $1.01. The company had a trading volume of 214,948 shares, compared to its average volume of 158,929. The firm has a market capitalization of $75.13, a PE ratio of -4.39 and a beta of -0.85. ContraFect Corp has a 12-month low of $0.80 and a 12-month high of $2.50.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.